Browsing by Author "Arslan, Cagatay"

Now showing 1 - 5 of 5

Enhancing Outcomes in mCRPC: The Impact of Androgen Receptor Inhibitor Sequencing before 177Lu-PSMA-617 Therapy
(Lippincott Williams & Wilkins, 2025) Yazgan, Coskun; Kayas, Kamil; Kapar, Caner; Oztekin, Sura; Arslan, Cagatay; Urun, Yuksel; Ceylan, Furkan
Citation - WoS: 1
Citation - Scopus: 1
Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice
(Elsevier Inc., 2023) Tural D.; Arslan C.; Selcukbiricik F.; Olmez O.F.; Akar E.; Erman M.; Ürün Y.; Akar, Emre; Olmez, Omer Fatih; Selcukbiricik, Fatih; Erman, Mustafa; Arslan, Cagatay; Tural, Deniz; Kilickap, Saadettin
Background: In this study, we report real-world results from the 5-year follow-up data of urothelial carcinoma patients treated with immune checkpoint blockade therapies (ICTs). Patients and Methods: Metastatic urothelial carcinoma patients treated with at least one course of ICT were included in the study. The primary endpoint was overall response rate (ORR), and secondary endpoints were overall survival (OS), progression-free survival (PFS), duration of treatment with ICT, and safety. Median follow-up, PFS, and OS were estimated by using the Kaplan-Meier method. Results: Data of 201 eligible patients were analyzed. The median age of the patients was 66 (37-86) years, and 156 (84.3%) were male. The majority of patients (94.6%) had Eastern Cooperative Oncology Group (ECOG) PS scores of 0 to 1 and primary tumor in the bladder was predominant (87.5%). The median follow-up time was 54 (1.15-65) months. The rate of complete response (CR) to ICT, partial response (PR) rate, and ORR were 10.4% (n = 21), 22.4% (n = 45), and 32.4% (n = 66), respectively. The median duration of response (DOR) was 34.8 months (95% confidence interval [CI], 29.2-42.1). Of the 66 patients who responded to treatment, 28 (42%) had an ongoing response at the time of the analysis. Median PFS and OS were 3.8 (2.6-5.8) months and 9.4 (7.4-11.4) months, respectively. The 5-year PFS and OS rates were 9.8% and 12.8%, respectively. Fifty-eight percent of patients experienced a treatment-related adverse event of any grade, and 33 (16.4%) patients had a grade 3 to 4 adverse event. Conclusion: This 5-year analysis of real-world data confirms the durable response and long-term survival with ICT in metastatic urothelial carcinoma patients. © 2022 Elsevier Inc.
Phase 1b/2 KEYNOTE-365 Cohort I: Pembrolizumab (Pembro) plus Carboplatin and Etoposide Chemotherapy (Chemo) or Chemo Alone for Metastatic Neuroendocrine Prostate Cancer (NEPC)
(Lippincott Williams & Wilkins, 2025) Gonzalez-Billalabeitia, Enrique; Von Amsberg, Gunhild; Arslan, Cagatay; Mehra, Niven; Emmenegger, Urban; Robbrecht, Debbie G. J.; Yu, Evan Y.
Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Colorectal, Gastroesophageal, and Pancreatic Cancers: A Global, Phase 3, Randomized, Placebo-Controlled Trial (RCT)
(Lippincott Williams & Wilkins, 2025) Munoz, Cesar; Soff, Gerald A.; Korantzis, Ippokratis; Al-Samkari, Hanny; Gonzalez Astorga, Beatriz; Arslan, Cagatay; Geredeli, Caglayan
Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
(Massachusetts Medical Soc, 2026) Munoz, Cesar; Soff, Gerald A.; Korantzis, Ippokratis; Astorga, Beatriz Gonzalez; Al-Samkari, Hanny; Arslan, Cagatay; Geredeli, Caglayan
Background Chemotherapy-induced thrombocytopenia (CIT) is a common complication of chemotherapy that is associated with bleeding, reduced relative dose intensity, and potentially worse outcomes. No widely available therapies are approved for CIT. Methods We conducted a phase 3, international, double-blind, randomized, placebo-controlled trial involving patients with persistent CIT (platelet count, <= 85 & times;109 per liter on trial day 1) who were receiving oxaliplatin-based multiagent cytotoxic chemotherapy for gastrointestinal cancers. Patients were randomly assigned in a 2:1 ratio to receive romiplostim or placebo for three chemotherapy cycles. The primary end point was the absence of CIT-induced modifications of the chemotherapy dose (reduction, delay, omission, or discontinuation) in both the second and third chemotherapy cycles. Results Of the 165 patients who underwent randomization (109 in the romiplostim group and 56 in the placebo group), 75% had colorectal cancer, 13% had gastroesophageal cancer, and 12% had pancreatic cancer; 72% of the patients in the romiplostim group and 61% of those in the placebo group had stage 4 disease. The percentage of patients with no CIT-induced modifications of the chemotherapy dose was 84% (92 of 109 patients) with romiplostim and 36% (20 of 56 patients) with placebo, which corresponded to an odds ratio of 10.16 (95% confidence interval [CI], 4.44 to 23.72; P<0.001) and a risk ratio of 2.77 (95% CI, 1.78 to 4.30; P<0.001). Adverse events of grade 3 or higher occurred in 37% of the patients who received romiplostim and in 22% of those who received placebo, which primarily reflected chemotherapy effects. Adverse events that were considered by the investigator to be related to romiplostim or placebo occurred in 12% of patients who received romiplostim and in 7% who received placebo, with the most frequent being nausea (2% in each group) and headache (2% in the romiplostim group); none were serious or led to death or discontinuation of romiplostim, placebo, or chemotherapy. Thromboembolic events occurred in 2% of patients who received romiplostim and in no patients who received placebo. Conclusions In this phase 3, placebo-controlled trial, romiplostim was efficacious in treating CIT. (Funded by Amgen and the Biomedical Advanced Research and Development Authority; RECITE ClinicalTrials.gov number, NCT03362177.)